Share on StockTwits

Infinity Pharmaceuticals (NASDAQ:INFI) was upgraded by equities research analysts at Wedbush to a “neutral” rating in a research note issued to investors on Wednesday.

Infinity Pharmaceuticals (NASDAQ:INFI) traded up 48.53% on Wednesday, hitting $16.22. The stock had a trading volume of 11,152,538 shares. Infinity Pharmaceuticals has a one year low of $8.40 and a one year high of $21.60. The stock has a 50-day moving average of $10.43 and a 200-day moving average of $11.30. The company’s market cap is $788.1 million.

Infinity Pharmaceuticals (NASDAQ:INFI) last issued its quarterly earnings data on Tuesday, August 5th. The company reported ($0.78) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.84) by $0.06. During the same quarter in the previous year, the company posted ($0.68) earnings per share. The company’s revenue for the quarter was up NaN% on a year-over-year basis. On average, analysts predict that Infinity Pharmaceuticals will post $-3.48 earnings per share for the current fiscal year.

Other equities research analysts have also recently issued reports about the stock. Analysts at William Blair upgraded shares of Infinity Pharmaceuticals to an “outperform” rating in a research note on Wednesday, August 6th. Analysts at Morgan Stanley initiated coverage on shares of Infinity Pharmaceuticals in a research note on Wednesday, June 25th. They set an “overweight” rating and a $17.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Infinity Pharmaceuticals presently has an average rating of “Buy” and an average price target of $17.71.

Infinity Pharmaceuticals, Inc (NASDAQ:INFI) is a drug discovery and development company.

Receive News & Ratings for Infinity Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.